<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:16:32 -0700</creation_date>
  <update_date>2013-05-27 11:38:34 -0600</update_date>
  <accession>HMDBP03818</accession>
  <secondary_accessions>
    <accession>9406</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>Gliostatin</synonym>
    <synonym>PD-ECGF</synonym>
    <synonym>Platelet-derived endothelial cell growth factor</synonym>
    <synonym>TP</synonym>
    <synonym>TdRPase</synonym>
  </synonyms>
  <gene_name>TYMP</gene_name>
  <general_function>Involved in transferase activity, transferring glycosyl groups</general_function>
  <specific_function>May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro.
Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.
</specific_function>
  <pathways>
    <pathway>
      <name>Pyrimidine Metabolism</name>
      <smpdb_id>SMP00046</smpdb_id>
      <kegg_map_id>map00240</kegg_map_id>
    </pathway>
    <pathway>
      <name>dTMP biosynthesis via salvage pathway</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>Pyrimidine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00240</kegg_map_id>
    </pathway>
    <pathway>
      <name>Drug metabolism - other enzymes</name>
      <smpdb_id/>
      <kegg_map_id>map00983</kegg_map_id>
    </pathway>
    <pathway>
      <name>Bladder cancer</name>
      <smpdb_id/>
      <kegg_map_id>map05219</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB14467</accession>
      <name>Floxuridine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14513</accession>
      <name>Cidofovir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14576</accession>
      <name>Trifluridine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14684</accession>
      <name>Fluorouracil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15233</accession>
      <name>Capecitabine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00273</accession>
      <name>Thymidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02142</accession>
      <name>Phosphoric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00262</accession>
      <name>Thymine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01351</accession>
      <name>Deoxyribose 1-phosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00012</accession>
      <name>Deoxyuridine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00300</accession>
      <name>Uracil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60406</accession>
      <name>5'-Deoxy-5-fluorouridine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60393</accession>
      <name>5-Deoxyribose-1-phosphate</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>pyrimidine-nucleoside phosphorylase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity, transferring pentosyl groups</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity, transferring glycosyl groups</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular aromatic compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine base metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nitrogen compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular nitrogen compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase, nucleoside, nucleotide and nucleic acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase, nucleoside and nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleoside metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine nucleoside metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>phosphorylase activity</description>
      <go_id>GO:0004645</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>platelet-derived growth factor receptor binding</description>
      <go_id>GO:0005161</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>pyrimidine-nucleoside phosphorylase activity</description>
      <go_id>GO:0016154</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>thymidine phosphorylase activity</description>
      <go_id>GO:0009032</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>angiogenesis</description>
      <go_id>GO:0001525</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cell differentiation</description>
      <go_id>GO:0030154</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>chemotaxis</description>
      <go_id>GO:0006935</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>DNA replication</description>
      <go_id>GO:0006260</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>mitochondrial genome maintenance</description>
      <go_id>GO:0000002</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>pyrimidine nucleobase metabolic process</description>
      <go_id>GO:0006206</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>pyrimidine nucleoside catabolic process</description>
      <go_id>GO:0046135</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>pyrimidine nucleoside salvage</description>
      <go_id>GO:0043097</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>pyrimidine nucleotide metabolic process</description>
      <go_id>GO:0006220</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>22</chromosome_location>
    <locus>22q13.33</locus>
    <gene_sequence>&gt;1449 bp
ATGGCAGCCTTGATGACCCCGGGAACCGGGGCCCCACCCGCGCCTGGTGACTTCTCCGGG
GAAGGGAGCCAGGGACTTCCCGACCCTTCGCCAGAGCCCAAGCAGCTCCCGGAGCTGATC
CGCATGAAGCGAGACGGAGGCCGCCTGAGCGAAGCGGACATCAGGGGCTTCGTGGCCGCT
GTGGTGAATGGGAGCGCGCAGGGCGCACAGATCGGGGCCATGCTGATGGCCATCCGACTT
CGGGGCATGGATCTGGAGGAGACCTCGGTGCTGACCCAGGCCCTGGCTCAGTCGGGACAG
CAGCTGGAGTGGCCAGAGGCCTGGCGCCAGCAGCTTGTGGACAAGCATTCCACAGGGGGT
GTGGGTGACAAGGTCAGCCTGGTCCTCGCACCTGCCCTGGCGGCATGTGGCTGCAAGGTG
CCAATGATCAGCGGACGTGGTCTGGGGCACACAGGAGGCACCTTGGATAAGCTGGAGTCT
ATTCCTGGATTCAATGTCATCCAGAGCCCAGAGCAGATGCAAGTGCTGCTGGACCAGGCG
GGCTGCTGTATCGTGGGTCAGAGTGAGCAGCTGGTTCCTGCGGACGGAATCCTATATGCA
GCCAGAGATGTGACAGCCACCGTGGACAGCCTGCCACTCATCACAGCCTCCATTCTCAGT
AAGAAACTCGTGGAGGGGCTGTCCGCTCTGGTGGTGGACGTTAAGTTCGGAGGGGCCGCC
GTCTTCCCCAACCAGGAGCAGGCCCGGGAGCTGGCAAAGACGCTGGTTGGCGTGGGAGCC
AGCCTAGGGCTTCGGGTCGCGGCAGCGCTGACCGCCATGGACAAGCCCCTGGGTCGCTGC
GTGGGCCACGCCCTGGAGGTGGAGGAGGCGCTGCTCTGCATGGACGGCGCAGGCCCGCCA
GACTTAAGGGACCTGGTCACCACGCTCGGGGGCGCCCTGCTCTGGCTCAGCGGACACGCG
GGGACTCAGGCTCAGGGCGCTGCCCGGGTGGCCGCGGCGCTGGACGACGGCTCGGCCCTT
GGCCGCTTCGAGCGGATGCTGGCGGCGCAGGGCGTGGATCCCGGTCTGGCCCGAGCCCTG
TGCTCGGGAAGTCCCGCAGAACGCCGGCAGCTGCTGCCTCGCGCCCGGGAGCAGGAGGAG
CTGCTGGCGCCCGCAGATGGCACCGTGGAGCTGGTCCGGGCGCTGCCGCTGGCGCTGGTG
CTGCACGAGCTCGGGGCCGGGCGCAGCCGCGCTGGGGAGCCGCTCCGCCTGGGGGTGGGC
GCAGAGCTGCTGGTCGACGTGGGTCAGAGGCTGCGCCGTGGGACCCCCTGGCTCCGCGTG
CACCGGGACGGCCCCGCGCTCAGCGGCCCGCAGAGCCGCGCCCTGCAGGAGGCGCTCGTA
CTCTCCGACCGCGCGCCATTCGCCGCCCCCTCGCCCTTCGCAGAGCTCGTTCTGCCGCCG
CAGCAATAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>482</residue_number>
    <molecular_weight>49954.965</molecular_weight>
    <theoretical_pi>5.53</theoretical_pi>
    <pfams>
      <pfam>
        <name>Glycos_trans_3N</name>
        <pfam_id>PF02885</pfam_id>
      </pfam>
      <pfam>
        <name>Glycos_transf_3</name>
        <pfam_id>PF00591</pfam_id>
      </pfam>
      <pfam>
        <name>PYNP_C</name>
        <pfam_id>PF07831</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Thymidine phosphorylase
MAALMTPGTGAPPAPGDFSGEGSQGLPDPSPEPKQLPELIRMKRDGGRLSEADIRGFVAA
VVNGSAQGAQIGAMLMAIRLRGMDLEETSVLTQALAQSGQQLEWPEAWRQQLVDKHSTGG
VGDKVSLVLAPALAACGCKVPMISGRGLGHTGGTLDKLESIPGFNVIQSPEQMQVLLDQA
GCCIVGQSEQLVPADGILYAARDVTATVDSLPLITASILSKKLVEGLSALVVDVKFGGAA
VFPNQEQARELAKTLVGVGASLGLRVAAALTAMDKPLGRCVGHALEVEEALLCMDGAGPP
DLRDLVTTLGGALLWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAAQGVDPGLARAL
CSGSPAERRQLLPRAREQEELLAPADGTVELVRALPLALVLHELGAGRSRAGEPLRLGVG
AELLVDVGQRLRRGTPWLRVHRDGPALSGPQSRALQEALVLSDRAPFAAPSPFAELVLPP
QQ</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P19971</uniprot_id>
  <uniprot_name>TYPH_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1UOU</pdb_id>
    <pdb_id>2J0F</pdb_id>
    <pdb_id>2WK5</pdb_id>
    <pdb_id>2WK6</pdb_id>
  </pdb_ids>
  <genbank_gene_id>M63193</genbank_gene_id>
  <genecard_id>TYMP</genecard_id>
  <geneatlas_id>TYMP</geneatlas_id>
  <hgnc_id>HGNC:3148</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989 Apr 13;338(6216):557-62.</reference_text>
      <pubmed_id>2467210</pubmed_id>
    </reference>
    <reference>
      <reference_text>Finnis C, Goodey A, Courtney M, Sleep D: Expression of recombinant platelet-derived endothelial cell growth factor in the yeast Saccharomyces cerevisiae. Yeast. 1992 Jan;8(1):57-60.</reference_text>
      <pubmed_id>1580101</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22.  Nature. 1999 Dec 2;402(6761):489-95.</reference_text>
      <pubmed_id>10591208</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y: Angiogenic factor.  Nature. 1992 Apr 23;356(6371):668.</reference_text>
      <pubmed_id>1570012</pubmed_id>
    </reference>
    <reference>
      <reference_text>Asai K, Nakanishi K, Isobe I, Eksioglu YZ, Hirano A, Hama K, Miyamoto T, Kato T: Neurotrophic action of gliostatin on cortical neurons. Identity of gliostatin and platelet-derived endothelial cell growth factor. J Biol Chem. 1992 Oct 5;267(28):20311-6.</reference_text>
      <pubmed_id>1400349</pubmed_id>
    </reference>
    <reference>
      <reference_text>Usuki K, Saras J, Waltenberger J, Miyazono K, Pierce G, Thomason A, Heldin CH: Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun. 1992 May 15;184(3):1311-6.</reference_text>
      <pubmed_id>1590793</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nishino I, Spinazzola A, Hirano M: Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science. 1999 Jan 29;283(5402):689-92.</reference_text>
      <pubmed_id>9924029</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gamez J, Ferreiro C, Accarino ML, Guarner L, Tadesse S, Marti RA, Andreu AL, Raguer N, Cervera C, Hirano M: Phenotypic variability in a Spanish family with MNGIE.  Neurology. 2002 Aug 13;59(3):455-7.</reference_text>
      <pubmed_id>12177387</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Floxuridine</name>
        <accession>HMDB14467</accession>
      </metabolite>
      <reference>
        <reference_text>Hara Y: [5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]. Gan To Kagaku Ryoho. 1984 Oct;11(10):2133-43.</reference_text>
        <pubmed_id>6237613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Floxuridine</name>
        <accession>HMDB14467</accession>
      </metabolite>
      <reference>
        <reference_text>Ozawa S, Hamada M, Murayama N, Nakajima Y, Kaniwa N, Matsumoto Y, Fukuoka M, Sawada J, Ohno Y: Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver. Cancer Chemother Pharmacol. 2002 Dec;50(6):454-8. Epub 2002 Oct 26.</reference_text>
        <pubmed_id>12451471</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Floxuridine</name>
        <accession>HMDB14467</accession>
      </metabolite>
      <reference>
        <reference_text>Sadahiro S, Otani Y, Oya K, Ike H, Shimada H, Yamaguchi S, Hiki Y, Fujita H, Mitomi T: Thymidine phosphorylase expression and effect of doxifluridine: a phase II study.  Oncol Rep. 2001 Jul-Aug;8(4):753-8.</reference_text>
        <pubmed_id>11410777</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cidofovir</name>
        <accession>HMDB14513</accession>
      </metabolite>
      <reference>
        <reference_text>De Clercq E: The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. Med Res Rev. 2011 Jan;31(1):118-60. doi: 10.1002/med.20179.</reference_text>
        <pubmed_id>19844936</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Temmink OH, Comijn EM, Fukushima M, Peters GJ: Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1491-4.</reference_text>
        <pubmed_id>15571283</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Emura T, Nakagawa F, Fujioka A, Ohshimo H, Kitazato K: Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Oncol Rep. 2004 Feb;11(2):381-7.</reference_text>
        <pubmed_id>14719072</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL: Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct;26(8):794-9.</reference_text>
        <pubmed_id>18798063</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM: Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer. 2006 Sep 15;107(6):1383-90.</reference_text>
        <pubmed_id>16902987</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Temmink OH, Prins HJ, van Gelderop E, Peters GJ: The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br J Cancer. 2007 Jan 15;96(1):61-6. Epub 2006 Dec 19.</reference_text>
        <pubmed_id>17179993</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Bassler R, Buchwald W: [Experimental inflammation and fibrosis of the lung framework caused by ionizing rays. Light and electron microscopic studies]. Fortschr Geb Rontgenstr Nuklearmed. 1966 Feb;104(2):192-206.</reference_text>
        <pubmed_id>6010427</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorouracil</name>
        <accession>HMDB14684</accession>
      </metabolite>
      <reference>
        <reference_text>Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S: 5-Fluorouracil pharmacogenomics: still rocking after all these years?  Pharmacogenomics. 2011 Feb;12(2):251-65.</reference_text>
        <pubmed_id>21332317</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>de Bono JS, Twelves CJ: The oral fluorinated pyrimidines.  Invest New Drugs. 2001;19(1):41-59.</reference_text>
        <pubmed_id>11291832</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y: A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res. 2001 Aug;18(8):1190-202.</reference_text>
        <pubmed_id>11587492</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR: Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45.</reference_text>
        <pubmed_id>12481438</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Ishitsuka H, Shimma N, Horii I: [Discovery and development of novel anticancer drug capecitabine].  Yakugaku Zasshi. 1999 Dec;119(12):881-97.</reference_text>
        <pubmed_id>10630095</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Ishitsuka H: Capecitabine: preclinical pharmacology studies.  Invest New Drugs. 2000 Nov;18(4):343-54.</reference_text>
        <pubmed_id>11081570</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Endo M, Miwa M, Eda H, Ura M, Tanimura H, Ishikawa T, Miyazaki-Nose T, Hattori K, Shimma N, Yamada-Okabe H, Ishitsuka H: Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805.</reference_text>
        <pubmed_id>12866042</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4):291-7.</reference_text>
        <pubmed_id>10755317</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Patel A, Pluim T, Helms A, Bauer A, Tuttle RM, Francis GL: Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Cancer Chemother Pharmacol. 2004 May;53(5):409-14.</reference_text>
        <pubmed_id>15132128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Eliason JF, Megyeri A: Potential for predicting toxicity and response of fluoropyrimidines in patients.  Curr Drug Targets. 2004 May;5(4):383-8.</reference_text>
        <pubmed_id>15134221</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Fischel JL, Ciccolini J, Formento P, Ferrero JM, Milano G: Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. Anticancer Drugs. 2006 Aug;17(7):807-13.</reference_text>
        <pubmed_id>16926630</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Walko CM, Lindley C: Capecitabine: a review.  Clin Ther. 2005 Jan;27(1):23-44.</reference_text>
        <pubmed_id>15763604</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
